AzTrials
AzTrials

Transposition of Great VesselsNCT05809310

Effects Branch PA Stenting d-TGA, ToF and TA

A study testing Percutaneous intervention (stent) for PA stenosis in people with Transposition of Great Vessels and Tetralogy of Fallot, run by UMC Utrecht at 4 sites in Netherlands.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this randomized controlled trial is to identify the effects of percutaneous interventions for branch PA stenosis on exercise capacity in patients with d-TGA, ToF and TA. Read more about this study

Who is it for?
Ages 8 years and older
What is being tested?
Percutaneous intervention (stent) for PA stenosis
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
56 participants
Where
4 sitesNetherlands
Study dates
18 Apr 2023to 31 Dec 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 8 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • Patients with d-TGA post ASO, ToF or TA
  • ≥8 years

Who cannot join

  • One or more of the following inclusion criteria:
  • All class IIa indications for a branch PA intervention:
  • Persistent decreased RV function (based on gold standard CMR)
  • <18 years RVEF ≤55% (28)
  • ≥18 years RVEF<50% (29)
  • Progressive tricuspid regurgitation (TR) (≥moderate)
Show all 14Show fewer
  • Isolated bifurcation stenosis:
  • Significant unilateral stenosis (≥50%)
  • Borderline bilateral PA stenosis (40-70%)
  • Unbalanced perfusion (≤35/65%)
  • RV/LV pressure ratio > 2/3 based on echocardiography
  • Reduced lung perfusion or decreased objective exercise capacity (based of gold standard VO2 max during CPET)
  • <18 years VO2 peak <35 mL∙kg-1∙min-1 (boys) VO2 peak <30 mL∙kg-1∙min-1 (girls) (30)
  • ≥18 years VO2 peak <27 mL∙kg-1∙min-1 (men) VO2 peak <19 mL∙kg-1∙min-1 (women) (31)

Trial locations and contacts

4 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Hans Breur, MD, PhD contact

+31 88 75 754 59

h.breur@umcutrecht.nl

Renée Joosen, MSc contact

r.s.joosen-2@umcutrecht.nl

Netherlands4 sites, 4 recruiting
  • Amsterdam University Medical Center location AMC

    Amsterdam, 1105 AZ

    Nico A Blom, MD, PhD, N.A.Blom@amsterdamumc.nl

    Renée S Joosen, MSc, r.s.joosen-2@umcutrecht.nl

    Not yet recruiting
  • Leiden University Medical Center

    Leiden, 2333 ZA

    Nico A Blom, MD, PhD, N.A.Blom@lumc.nl

    Renée S Joosen, MSc, r.s.joosen-2@umcutrecht.nl

    Not yet recruiting
  • Erasmus Medical Center

    Rotterdam, 3015 CN

    Thomas B Krasemann, MD, PhD, t.krasemann@erasmusmc.nl

    Renée S Joosen, MSc, r.s.joosen-2@umcutrecht.nl

    Not yet recruiting
  • UMC Utrecht/WKZ

    Utrecht, 3584 CX

    Johannes MPJ Breur, MD, PhD, 0031887575459, h.breur@umcutrecht.nl

    Renée S Joosen, MSc, r.s.joosen-2@umcutrecht.nl

    Recruiting

Other trials in Netherlands

About this study

Official title: The Effects of Branch Pulmonary Artery Stenting in d-TGA, ToF and TA: a Randomized Control Trial

The goal of this randomized controlled trial is to identify the effects of percutaneous interventions for branch PA stenosis on exercise capacity in patients with d-TGA, ToF and TA.

The main question[s] it aims to answer are:

Read more

The primary study objective is to identify the effects of percutaneous interventions for branch PA stenosis on exercise capacity in patients with d-TGA, ToF and TA. The secondary objectives are 1) to assess the effects of percutaneous interventions for branch PA stenosis on RV function and 2) to define early markers for RV function and adaptation to improve timing of these interventions.

Participants will undergo the same series of examinations at baseline and approximately 6 months follow-up (within 6 week time-range) as part of standard care: conventional transthoracic echocardiogram (TTE), cardiopulmonary exercise testing (CPET) and conventional Cardiac Magnetic Resonance (CMR) including a low dose dobutamine stress MRI to assess RV functional reserve. The low dose dobutamine stress MRI will be performed in the interventional group from the UMC Utrecht/WKZ and Erasmus MC because the LUMC and AUMC do not have a suitable infrastructure for the low dose dobutamine stress MRI and this cannot be achieved throughout the duration of this study. The baseline CMR in the interventional group will be performed as close as possible prior to the intervention but maximal 4 weeks prior to the intervention. In addition, the intervention group will undergo standard RV pressure measurements during the intervention. Quality of life (QoL) questionnaires will be obtained at baseline and 2 weeks post intervention (intervention group) or a similar time range in the control group, which is based on experts opinion. TTE, CPET and conventional CMR will be performed within 2-4 years follow-up to assess the long-term effects of percutaneous PA interventions.

Researchers will compare the difference in VO2 max (% predicted) between the interventional group (TGA, ToF or TA patients with a class II indication for a PA intervention who will undergo a percutaneous intervention for a PA stenosis) and the control group (TGA, ToF or TA patients with a class II indication for a PA intervention who will undergo conservative management)

Read the detailed description

Rationale: Postoperative survival of patients with dextro transposition of the great arteries (d-TGA), Tetralogy of Fallot (ToF) and Truncus Arteriosus (TA) has increased over the last decades due to advances in operative techniques and perioperative care. Despite postoperative survival has increased, morbidity of these patients increases during long-term follow-up with a high need for reinterventions. Right ventricular outflow tract (RVOT) obstructions are the most common indication for a reintervention and percutaneous branch pulmonary artery (PA) interventions account for a significant number of these reinterventions. However, the effects of percutaneous branch PA interventions on exercise capacity, RV function and RV adaptation of patients with d-TGA, ToF and TA remains largely unknown. In addition, there is no consensus about the optimal timing for percutaneous interventions for branch PA stenosis in international guidelines.

Objective: The primary study objective is to identify the effects of percutaneous interventions for branch PA stenosis on exercise capacity in patients with d-TGA, ToF and TA. The secondary objectives are 1) to assess the effects of percutaneous interventions for branch PA stenosis on RV function and 2) to define early markers for RV function and adaptation to improve timing of these interventions.

Study design: This is a multicenter randomized controlled trial. Patients will be included from the following Dutch interventional centers for congenital heart disease: UMC Utrecht/WKZ (sponsor), LUMC/AUMC and Erasmus MC. During this trial there will be two groups: 1. a group of patients with d-TGA, ToF and TA who will undergo a percutaneous intervention for a branch PA stenosis according to standard care (intervention group) and 2. a group of patients with d-TGA, ToF and TA with a similar degree of pulmonary stenosis as group 1 (class IIa indication) who will undergo conservative management for a branch PA stenosis according to standard care (control group). If necessary, the control group will be able to undergo a percutaneous intervention for branch PA stenosis after the examinations at approximately 6 months follow-up, or sooner in case of symptoms. Patients from both groups will undergo the same series of examinations at baseline and approximately 6 months follow-up (within 6 week time-range) as part of standard care: conventional transthoracic echocardiogram (TTE), cardiopulmonary exercise testing (CPET) and conventional Cardiac Magnetic Resonance (CMR) including a low dose dobutamine stress MRI to assess RV functional reserve. The low dose dobutamine stress MRI will be performed in the interventional group from the UMC Utrecht/WKZ and Erasmus MC because the LUMC and AUMC do not have a suitable infrastructure for the low dose dobutamine stress MRI and this cannot be achieved throughout the duration of this study. The baseline CMR in the interventional group will be performed as close as possible prior to the intervention but maximal 4 weeks prior to the intervention. In addition, the intervention group will undergo standard RV pressure measurements during the intervention. Quality of life (QoL) questionnaires will be obtained at baseline and 2 weeks post intervention (intervention group) or a similar time range in the control group, which is based on experts opinion. TTE, CPET and conventional CMR will be performed within 2-4 years follow-up to assess the long-term effects of percutaneous PA interventions.

Study population: d-TGA post ASO, ToF or TA patients ≥8 years old will be included if they have a class IIa indication for a percutaneous intervention for branch PA stenosis according to the international guidelines. Patients will be excluded if they contraindications for one of the examinations.

Main study parameters/endpoints: the difference in VO2 max (% predicted) as parameter for exercise capacity between the interventional and control group.

Being tested
Percutaneous intervention (stent) for PA stenosis
Keywords
Exercise capacity
Medical subject headings
Transposition of Great Vessels, Tetralogy of Fallot, Truncus Arteriosus, Persistent, Ventricular Dysfunction, Right, Heart Defects, Congenital

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Percutaneous intervention (stent) for PA stenosisProcedure or surgery

    Percutaneous intervention (stent placement) in one or both of the branch pulmonary arteries

Study groups in NCT05809310
Study groupRoleWhat they receive
Interventional groupExperimentalPercutaneous intervention for PA stenosis
Receives: Procedure: Percutaneous intervention (stent) for PA stenosis
Control groupNo interventionConservative management (percutaneous intervention for PA stenosis 6 months postponed)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from baseline VO2max as percentage of predicted at 6 months as indication of exercise capacity

    using cardiopulmonary exercise test on a treadmill

    Measured: change between baseline and 6 months follow-up

Secondary outcomes (18)
  1. Technical success using invasive right ventricular and pulmonary artery pressures and gradients

    Technical success of the intervention using invasive right ventricular and pulmonary artery pressures and gradients

    Measured: after the intervention, an average of 1 month after baseline

  2. Peak workload (W)

    using cardiopulmonary exercise test on a treadmill

    Measured: at baseline, 6 months follow-up and 2-4 years follow-up

  3. Peak workload (% predicted)

    using cardiopulmonary exercise test on a treadmill

    Measured: at baseline, 6 months follow-up and 2-4 years follow-up

  4. O2 pulse (ml)

    using cardiopulmonary exercise test on a treadmill

    Measured: at baseline, 6 months follow-up and 2-4 years follow-up

  5. O2 pulse (% predicted)

    using cardiopulmonary exercise test on a treadmill

    Measured: at baseline, 6 months follow-up and 2-4 years follow-up

  6. VE/VCO2 slope

    using cardiopulmonary exercise test on a treadmill

    Measured: at baseline, 6 months follow-up and 2-4 years follow-up

  7. Right ventricular ejection fraction (%)

    using CMR

    Measured: at baseline, 6 months follow-up and 2-4 years follow-up

  8. RV strain (%)

    using speckle tracking echocardiography and CMR feature tracking

    Measured: at baseline, 6 months follow-up and 2-4 years follow-up

  9. RV fractional area change (%)

    using echocardiography

    Measured: at baseline, 6 months follow-up and 2-4 years follow-up

  10. RV pressure (mmHg)

    using echocardiography (TI gradient)

    Measured: at baseline, 6 months follow-up and 2-4 years follow-up

  11. RV end-systolic elastance

    using pressure-volume analysis

    Measured: before and after the intervention, an average of 1 month after baseline

  12. RV end systolic volume (ml and ml/m2)

    using CMR

    Measured: at baseline, 6 months follow-up and 2-4 years follow-up

  13. RV end diastolic volume (ml and ml/m2)

    using CMR

    Measured: at baseline, 6 months follow-up and 2-4 years follow-up

  14. RV functional reserve

    RVEF dobutamine - RVEF rest using a low dose dobutamine stress MRI

    Measured: at baseline and 6 months follow-up in the interventional group from UMC Utrecht and Erasmus MC

  15. RV mass (g and g/m2)

    using CMR

    Measured: at baseline, 6 months follow-up and 2-4 years follow-up

  16. Right ventricular pulmonary arterial (RV-PA) coupling

    using pressure-volume analysis

    Measured: before and after the intervention, an average of 1 month after baseline

  17. Lung perfusion (%)

    using CMR

    Measured: at baseline, 6 months follow-up and 2-4 years follow-up

  18. Quality of Life (QoL) in 4 domains: health and related activities, emotional, social and school/work

    using PedsQL questionnaire

    Measured: at baseline and 2 weeks follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Apr 2023
  2. Study start18 Apr 2023
  3. Primary completion31 Dec 2027 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
56 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05809310
Sponsor's protocol ID
NL81160
Status last verified
Mar 2025
First submitted
15 Mar 2023
Last updated
30 Mar 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: We will publish the results in peer-reviewed journals and present them at meetings and conferences. As the data is privacy-sensitive, the database will not be publically available. A request for a collaboration can be made via DataverseNL.

Publications

  • Joosen RS, Voskuil M, Krasemann TB, Blom NA, Krings GJ, Breur JMPJ; Outreach consortium. The effects of percutaneous branch pulmonary artery interventions in biventricular congenital heart disease: study protocol for a randomized controlled Dutch multicenter interventional trial. Trials. 2024 Sep 3;25(1):581. doi: 10.1186/s13063-024-08436-8.

    PubMed 39227910

Questions about this trial

What is this clinical trial studying?

A study testing Percutaneous intervention (stent) for PA stenosis in people with Transposition of Great Vessels and Tetralogy of Fallot, run by UMC Utrecht at 4 sites in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 30 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Hans Breur, MD, PhD (+31 88 75 754 59, h.breur@umcutrecht.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline VO2max as percentage of predicted at 6 months as indication of exercise capacity (time frame: change between baseline and 6 months follow-up). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05809310, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Mar 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in